This content is machine translated Uveal melanoma Development of a CAR T-cell therapy for uveal melanoma T cells that are endowed with tumor specificity through the expression of a chimeric antigen recept or (CAR) are becoming increasingly important. They are already increasingly being used in adoptive… CME-Test
View Post 27 min This content is machine translated Uveal melanoma Development of a CAR T-cell therapy for uveal melanoma T cells that are endowed with tumor specificity through the expression of a chimeric antigen recept or (CAR) are becoming increasingly important. They are already increasingly being used in adoptive… CME-Test
View Post 9 min This content is machine translated Locally advanced/metastatic breast carcinoma 44th San Antonio Breast Cancer Symposium: Best Of From December 7-10, 2021, the 44th San Antonio Breast Cancer Symposium took place in a physical-virtual hybrid event. In a series of exciting lectures, the latest clinical and preclinical findings…
View Post 3 min This content is machine translated Breast Cancer News from the world of HER2-targeted treatment options Breast carcinoma is the most common malignant tumor in women. The prognosis of patients is determined primarily by the stage and biology of the disease. Innovative therapeutics and new treatment…
View Post 8 min This content is machine translated Gynecological oncology The treatment of breast carcinoma over time The treatment of breast carcinoma has changed significantly in recent years. Individualized therapy management that addresses the particular specificity of the breast carcinoma is now the focus.
View Post 2 min This content is machine translated Breast Cancer The right therapy for aggressive tumors in young women Especially in young women, breast cancer often presents as biologically aggressive. Nevertheless, the chances of survival are good if the right therapy is chosen.
View Post 11 min This content is machine translated From chemotherapy to immunotherapy Current system therapy in metastatic non-small cell lung cancer. Detailed molecular diagnosis is now mandatory for non-small cell lung cancer (NSCLC). In the presence of a driver mutation, the corresponding tyrosine kinase inhibitor should be used in the first…
View Post 4 min This content is machine translated San Antonio Breast Cancer Symposium Modifications of neoadjuvant therapy New evaluations of the GeparSepto trial were presented at the San Antonio Breast Cancer Symposium. In this study, nab-paclitaxel is compared with solvent-containing paclitaxel as part of the neoadjuvant treatment…
View Post 10 min This content is machine translated From high-dose chemotherapy to gene expression. Developments in adjuvant chemotherapy of breast carcinoma. The use of multigene testing is currently limited to the adjuvant setting in HER2-negative luminal breast carcinoma and allows reproducible predictions of recurrence risk. The tests will lead to fewer…
View Post 4 min This content is machine translated Gastric Cancer HER2 inhibition may also prolong survival in gastric cancer A new molecular genetic classification of gastric cancer into four subtypes was recently proposed as part of the Cancer Genome Atlas project, which identifies all gene defects in all known…
View Post 2 min This content is machine translated HSP90 inhibition A new therapeutic approach for breast cancer In an initial phase II study in metastatic breast cancer, the HSP90 inhibitor ganetespib has shown promising antitumor activity in HER2-positive and triple-negative breast cancer (TNBC). Due to the favorable…
